MARC Record from marc_columbia

LEADER: 04555pam a22004454a 4500
001 5216294
005 20221109234033.0
008 040608t20052005njua b 001 0 eng
010 $a 2004013542
016 7 $a101220028$2DNLM
020 $a1588290271 (hardcover : alk. paper)
035 $a(OCoLC)ocm55633965
035 $a(NNC)5216294
035 $a5216294
040 $aDNLM/DLC$cDLC$dYDX$dNLM$dOrLoB-B
042 $apcc
050 00 $aRC271.C35$bC345 2005
060 10 $aQV 269$bC1989 2005
082 00 $a616.99/4061$222
245 00 $aCamptothecins in cancer therapy /$cedited by Val R. Adams and Thomas G. Burke.
260 $aTotowa, N.J. :$bHumana Press,$c[2005], ©2005.
300 $axiii, 460 pages :$billustrations (some color) ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aCancer drug discovery and development
504 $aIncludes bibliographical references and index.
505 00 $g1.$tMechanism of action of topoisomerase 1 poisons /$rLeroy F. Liu and Shyamal D. Desai -- $g2.$tCrystallographic insight into the mechanism of drug-induced topoisomerase I DNA damage /$rAlex B. Burgin, Jr., Michael D. Feese, Bart L. Staker and Lance Stewart -- $g3.$tInhibitors of topoisomerase I function /$rSidney M. Hecht -- $g4.$tCytotoxic mechanisms of the topoisomerase I inhibitors /$rYves G. Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet and ZhiYong Liao -- $g5.$tBiochemical and genetic analyses of DNA topoisomerase 1-mediated DNA damage /$rRobert C. A. M. van Waardenburg and Mary-Ann Bjornsti -- $g6.$tPreclinical models for evaluating topoisomerase I-targeted drugs /$rAarti S. Juvekar, Joyee Thompson, Clinton F. Stewart and Peter J. Houghton -- $g7.$tMechanisms of resistance to camptothecins /$rZeshaan A. Rasheed and Eric H. Rubin -- $g8.$tRecent advances in camptothecin drug design and delivery strategies /$rThomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson and Lori J. Latus -- $g9.$tClinical experience with 9-aminocamptothecin : lessons for new drug development /$rChris H. Takimoto -- $g10.$tClinical studies of rubitecan (9-nitro 20(S) camptothecin) /$rHilary Hewes, Judith A. Smith and Claire Verschraegen -- $g11.$tIrinotecan : current clinical status and pharmacological aspects /$rLaurent P. Rivory -- $g12.$tClinical experience with topotecan /$rAimee K. Bence and Val R. Adams -- $g13.$tThe clinical development of lurtotecan : experience with water-soluble and liposomal forms /$rKeith T. Flaherty, James P. Stevenson, Christopher J. Twelves and Peter J. O'Dwyer -- $g14.$tPreclinical and clinical development of exatecan (DX-8951f) : a hexacyclic camptothecin analog /$rEric K. Rowinsky -- $g15.$tCamptothecins in the treatment of primary brain tumors /$rClinton F. Stewart, Markos Leggas and Henry S. Friedman -- $g16.$tCamptothecins in the treatment of lung cancer /$rPankaj Kumar, Missak Haigentz, Jr., Jorge Gamez and Roman Perez-Soler -- $g17.$tUse of camptothecins in the treatment of leukemia and related disorders /$rBenjamin M. F. Mow and Scott H. Kaufmann.
520 1 $a"In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers."--BOOK JACKET.
650 0 $aCamptothecin.$0http://id.loc.gov/authorities/subjects/sh94006761
650 0 $aCancer$xChemotherapy.$0http://id.loc.gov/authorities/subjects/sh85019497
650 12 $aCamptothecin$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D002166Q000627
650 12 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 22 $aAntineoplastic Agents, Phytogenic$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000972Q000627
650 22 $aCamptothecin$xanalogs & derivatives.$0https://id.nlm.nih.gov/mesh/D002166Q000031
650 22 $aCamptothecin$xpharmacology.$0https://id.nlm.nih.gov/mesh/D002166Q000494
700 1 $aBurke, Thomas G.,$cPhD.$0http://id.loc.gov/authorities/names/n2004121568
700 1 $aAdams, Val R.$0http://id.loc.gov/authorities/names/n2004121569
830 0 $aCancer drug discovery and development.$0http://id.loc.gov/authorities/names/n88538383
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip0418/2004013542.html
852 00 $boff,hsl$hRC271.C35$iC345 2005